DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for Herpes simplex infection — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHerpes simplex infection maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for herpes simplex infection is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
An open study of continuous oral cyclooxygenase inhibitors (ibuprofen or indomethacin) reported reduced incidence and frequency of recurrent eruptions in nine of 16 patients with herpes simplex virus infection. A retrospective analysis of seven of those cases suggested that natural killer cell enhancement assays might predict clinical outcome, but the study was small, uncontrolled, and did not provide survival or response rates.
A double-blind, placebo-controlled trial of oral lysine hydrochloride (400 mg three times a day) in 21 patients with frequently recurring herpes simplex infection found no substantial benefit for episode frequency, duration, or severity, either as treatment for active episodes or as prophylaxis against recurrences. The authors concluded that lysine is unlikely to improve frequently recurrent herpes simplex infections in the majority of patients.
A 1968 review stated that treatment for herpes simplex remained nonspecific and symptomatic, recommending antibiotics for secondary infection, analgesics, antipyretics, drying liquids or ointments, the drug idoxuridine, or removal of triggering circumstances. A 1977 review noted that no cure was available, that antiviral therapy was the main treatment modality used orally, intravenously, or topically to inhibit viral replication, and that immunologic advances were promising but still under study.
What is still missing are large, randomised, placebo-controlled trials of cyclooxygenase inhibitors for herpes simplex prophylaxis, any trial data on idoxuridine from controlled settings, and a reliable biomarker to stratify patients who might respond to immunomodulatory approaches. No drug mentioned in these abstracts has been shown to eradicate latent virus or prevent all recurrences.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Dermatology · 1990 · 23 citations
The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections
AbstractIn an open study, continuous oral therapy with cyclooxygenase inhibitors (ibuprofen or indomethacin) reduced the incidence and frequency of recurrent eruptions in nine of 16 patients with herpes simplex virus infection. Retrospective analysis of seven cases indicated that natural killer cell enhancement assays might allow us to predict the clinical outcome of such treatment.
Failure of Lysine in Frequently Recurrent Herpes Simplex Infection
Abstract• Lysine has been claimed to be effective in the treatment and prevention of episodes of recurrent herpes simplex (HS) infection. We carried out a double-blind, placebo-controlled trial of oral lysine hydrochloride therapy (400 mg, three times a day) in a group of 21 patients in good general health with a history of frequently recurring infection. Using our measures of episode frequency, duration, and severity, we were unable to detect any substantial benefit of lysine therapy either as a treatment for episodes in progress or as a prophylactic drug for the prevention of recurrences. We conclude that it is unlikely that lysine improves frequently recurrent HS infections in the majority of patients. (<i>Arch Dermatol</i>1984;120:48-51)
AbstractTreatment for herpes simplex, a viral disease, remains nonspecific and symptomatic. Yet there are some measures the physician can take. He can prevent secondary infections with antibiotics, give analgesics and antipyretics, use drying liquids or ointments to relieve local lesions, try the new drug idoxuridine, or remove or modify circumstances that bring on an attack.
AbstractHerpes simplex virus persists in a latent form for the life of its host, periodically reactivating and often resulting in significant psychosocial distress for the patient. Currently no cure is available. Antiviral therapy is the main treatment modality, used either orally, intravenously, or topically to prohibit further replication of the virus and thereby minimize cellular destruction. However, immunologic advances in the treatment and prevention of herpes simplex infections are promising and continue to be studied.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
